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targeted Hb level in Ferrum lek group was 4255.68 rubles and
5990.76 rubles in Fenuls group. Mean cost of 1 g/L Hb increas-
ing is 144.05 (49.8–287.7) rubles with Ferrum Lek and 224.72
(69.61–896.6) rubles with Fenuls. CONCLUSION: Ferrum Lek
is cost-effective medicine for treating iron-deﬁcient anemia in
elderly patients with gastrointestinal co-morbidities in compari-
son with Fenuls.
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OBJECTIVES: To evaluate the cost-effectiveness and Positive
Investment Interval (PII) of ADVATE [Antihemophilic Factor
(Recombinant), Plasma/Albumin-Free Method, PFM] as an
on-demand/prophylactic modality for hemophilia A (HA) treat-
ment compared to the best current Finnish treatment practice
(Kogenate) in a scenario where a pathogen emerges and
is transmitted trough non-PFM methods as the Hepatitis C
virus (HCV) in the 1980’s. METHODS: Incremental cost-
effectiveness analysis was performed using probabilistic simu-
lation to depict uncertainty. Conservative information related
to treatment practices, costs and survival in Finland were gath-
ered from literature and clinical experts. HIV and HBV were
excluded from the modeling, because only 2 HIVs have been
transmitted through coagulant products to Finnish HA patients
and efﬁcient vaccinations against HBV infection exists. Our
innovation, PII, is discussed elsewhere. Here, PII was used to
assess the interval when the extra treatment costs of ADVATE
are compensated by the treatment costs of emerging pathogen
(i.e. interval when no pathogens should emerge, if non-PFM
method is used). RESULTS: Current treatment practice was
dominated by the ADVATE scenario. 18 years old HA male
with and without pathogen transmission had survival estimates
of 48 and 55 years, respectively. The expected difference in
survival was 3.48 years (51% less pathogen transmissions).
Mean treatment cost differences were 7,500–50,200 €/year and
213,700–2,381,600 €/lifetime favoring ADVATE. All PIIs for
annual ADVATE investment favored ADVATE and were 1–7
years depending on patient’s weight, age, and treatment modal-
ity. When production losses and discounting of costs and effec-
tiveness (5%) were included in sensitivity analysis, the relative
differences increased (e.g. PIIs became 1–9 years due to pro-
duction losses). CONCLUSION: ADVATE improves survival, is
cost-effective and offers good long-term investment in the treat-
ment of hemophilia A, when known/unknown pathogens trans-
mitted through non-PFM methods emerge. When investment’s
safety is of concern, PII offers new hands-on interpretation for
the political discussion.
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OBJECTIVES: To conduct a cost per QALY analysis of intrave-
nous versus oral administration of iron, in anemia in Oncology,
Chronic Kidney Disease (CKD) and Post-partum patients.
METHODS: Intravenous iron supplementation has been shown
to improve Hb response to EPO treatment, and to decrease EPO
dosage requirements in patients with chronic anemia. Intrave-
nous iron is more costly but also more effective than oral iron in
treatment of anemia. A Markov model was developed for esti-
mating incremental costs and QALYs in Oncology and CKD
patients. Incremental costs were estimated for iron therapy,
Erythropoietin (EPO) administration, Blood transfusion, and
outpatient visits. QALY gains were estimated by linking Hb
levels to QALY weights. A piggy-back approach was used for
estimating costs and QALYs in anemia treatment in Post-Partum
patients. Swedish prices and data representing Swedish treatment
patterns and patient characteristics are derived from national
databases and publications. RESULTS: In CKD patients, the cost
of intravenous iron is offset by cost savings for EPO. Intravenous
iron successfully corrects the anemia quicker than oral iron,
resulting in a gain of 0.065 QALYs. In Oncology, the cost of IV
iron is also offset by savings in EPO costs. Intravenous iron
corrects the anemia quicker than oral iron and reaches a higher
Hb level, with a resulting gain of 0.0759 QALYs. In post-partum
patients, Hb is more quickly corrected with intravenous iron,
leading to a QALY gain of 0.0086 during a six week time frame.
The incremental cost for intravenous iron is 700 SEK, with a
resulting cost of 68,000 SEK per QALY gained. CONCLUSION:
Intravenous iron is a cost-effective alternative to oral iron, in
treatment of iron deﬁciency anemia in oncology, CKD and post-
partum patients.
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OBJECTIVES: Haemophilia patients with inhibitors character-
istically have high annual drug costs and other health care
related costs. There are essentially three treatment options:
NovoSeven, FEIBA or ITT followed by regular F8 treatment.
Aim: This cost-minimization simulation examines the treatment
costs of NovoSeven versus FEIBA and ITT/F8 for haemophilia
A/B patients with inhibitors. METHODS: The simulation is
based on a standard set of assumptions for an average severe
haemophilia patient. First, primary prophylaxis treatment is
deﬁned by daily treatment on an annual basis of 50 ìG/KG for
NovoSeven and 40 IU/KG for FEIBA. ITT-F8 treatment follows
the Bonn Protocol for ITT at 300 IU/KG followed by F8 at
15 IU/KG. Second, we assume 2 breakthrough bleeds per
month. Third, the patients weight changes each year through-
out a 21 year child-adolescent-manhood life cycle time series
model according to average yearly weight changes for boys in
the standard population. Fourth, costs are based on estimated
average global realised wholesaler purchaser prices in EUROS.
ITT-F8 costs 0.7271 EUROS for an IU/KG. FEIBA costs
1.143216 EUROS for an IU/KG. NovoSeven costs 0.9191
EUROS for an ìG/KG. Costs are also discounted at a rate of
3.5 percent a year over time. RESULTS: Annual N7 costs for a
70 KG patient are 990.662 EUROS per year. Annual FEIBA
costs for a 70 KG patient are 1.168.367 EUROS per year.
Annual ITT treatment is 11.146.504 EUROS and annual F8
treatment costs are 277.679 EUROS. CONCLUSION: Novo
Seven is slightly cheaper compared to FEIBA for certain dosing
regimens. NovoSeven is also cheaper than ITT-F8 for the ﬁrst
6–7 years after treatment begins.
Abstracts A281
